Repair of potentially lethal damage by total and quiescent cells in solid tumors following a neutron capture reaction.
OBJECTIVE
We analyzed the time-course of changes in the sensitivity of total (proliferating + quiescent and quiescent (Q) cell populations within solid tumors in situ following a neutron capture reaction and compared it with that after gamma-ray irradiation.


METHODS
After continuous labeling of proliferating cells with BrdU for 5 days, mice bearing SCC VII tumors received thermal neutron irradiation with or without a (10)B-labeled compound (sodium [(10)B]borocaptate, BSH, or DL-p-[(10)B]boronophenylalanine, BPA), or gamma-ray irradiation. From 5 min to 72 h after treatment, tumors were excised, minced, and trypsinized. Cell suspensions were incubated for 48 h with the cytokinesis blocker cytochalasin-B. The micronucleus frequency for BrdU-unlabeled cells, Q cells at treatment, was then determined by immunofluorescence staining for BrdU. The micronucleus frequency for total cells was obtained from tumors that had not been pretreated with BrdU labeling. The sensitivity was evaluated in terms of the frequency of induced micronuclei in binuclear tumor cells (micronucleus frequency).


RESULTS
Overall, Q cells showed greater repair capacities than total cells. gamma-Ray irradiation and neutron irradiation with BPA induced larger repair capacities in each cell population. In contrast, thermal neutron irradiation without a (10)B-labeled compound induced the smallest repair capacity in both cell populations. The use of a (10)B-labeled compound, especially BPA, widened the difference in sensitivity between total and Q cells, resulted in an increase in repair capacity in both cell populations, and made the repair patterns of the two cell populations look like those induced by gamma-ray irradiation.


CONCLUSIONS
Differences in sensitivity and repair patterns following the neutron capture reaction were thought to depend on differences in the distribution of the (10)B-labeled compound between the proliferating and Q cell populations.
Masunaga
S
S
Radiation Oncology Research Laboratory, Research Reactor Institute, Kyoto University, Noda, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan. smasuna@rri.kyoto-u.ac.jp
Ono
K
K
Suzuki
M
M
Sakurai
Y
Y
Takagaki
M
M
Kobayashi
T
T
Kinashi
Y
Y
Akaboshi
M
M
D000818:Animals; D001894:Borohydrides / Q000627:therapeutic use; D001896:Boron Compounds / Q000627:therapeutic use; D016754:Boron Neutron Capture Therapy; D001973:Bromodeoxyuridine; D002294:Carcinoma, Squamous Cell / Q000473:pathology* / Q000532:radiotherapy*; D002455:Cell Division / Q000187:drug effects / Q000528:radiation effects; D003571:Cytochalasin B / Q000494:pharmacology; D004249:DNA Damage; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005720:Gamma Rays; D051379:Mice; D008809:Mice, Inbred C3H; D015162:Micronucleus Tests; D009368:Neoplasm Transplantation; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D012680:Sensitivity and Specificity; D013438:Sulfhydryl Compounds / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
D001894:Borohydrides; D001896:Boron Compounds; D013438:Sulfhydryl Compounds; C014651:mercaptoundecahydrododecaborate; D003571:Cytochalasin B; D010649:Phenylalanine; D001973:Bromodeoxyuridine; C033685:4-boronophenylalanine